aminobenzoic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2049 150-13-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • 4-aminobenzoic acid
  • aminobenzoate potassium
  • p-aminobenzoic acid
  • 4-aminobenzenecarboxylic acid
  • 4-carboxy phenyl aniline
  • aminobenzoic acid
  • 4-Aminobenzoate
An aminobenzoic acid isomer that combines with pteridine and GLUTAMIC ACID to form FOLIC ACID. The fact that 4-aminobenzoic acid absorbs light throughout the UVB range has also resulted in its use as an ingredient in SUNSCREENS.
  • Molecular weight: 137.14
  • Formula: C7H7NO2
  • CLOGP: 0.98
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 63.32
  • ALOGS: -1.49
  • ROTB: 1

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.488 Moderate 0.74
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.446 Moderate 0.74
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 5.333 10^-6 cm/s Moderate 0.74
dh-clint Dog hepatocyte intrinsic clearance 1.986 uL/min/10^6 cells Moderate 0.74
dppb Dog plasma protein binding (% unbound) 35.250 % Moderate 0.74
fcs-ppb Fetal calf serum protein binding (% unbound) 70.190 % Moderate 0.74
herg hERG pIC50 4.326 pIC50 Moderate 0.74
hh-clint Human hepatocyte intrinsic clearance 3.013 uL/min/10^6 cells Moderate 0.74
hlm-clint Human liver microsomal intrinsic clearance 3.664 uL/min/mg protein Moderate 0.74
hppb Human plasma protein binding (% unbound) 42.120 % Moderate 0.74
kinase-safety-class ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 60
kinase-selectivity-class ACVR2A,ACVR2B,AURKA,AURKB,AXL,BRAF,CAMK2B,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,MAP2K3,MAP2K6,MAP3K14,MAP3K21,MAPK7,MARK4,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2 33
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.540 Moderate 0.74
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.394 Moderate 0.74
mh-clint Mouse hepatocyte intrinsic clearance 2.911 Moderate 0.74
mppb Mouse plasma protein binding (% unbound) 70.480 Moderate 0.74
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.276 Moderate 0.74
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 67.830 % Moderate 0.74
rat-kpuu-brain Rat brain Kpuu 0.525 % Moderate 0.74
rh-clint Rat hepatocyte intrinsic clearance 4.111 uL/min/10^6 cells Moderate 0.74
rh-fuinc Rat hepatocyte fraction unbound in incubation 85.770 % Moderate 0.74
rppb Rat plasma protein binding (% unbound) 42.680 % Moderate 0.74
solubility-dd Solubility at pH 7.4 in DMSO 970.510 uM Moderate 0.74

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonia aspiration 191.16 168.87 38 184 40902 90587323
Coma 169.44 168.87 38 184 72594 90555631

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 220.62 145.64 74 4420 13382 42603459
Blood phosphorus increased 201.83 145.64 68 4426 12457 42604384
Myasthenia gravis 199.91 145.64 72 4422 16065 42600776
Appendicitis 193.36 145.64 75 4419 20538 42596303
Blood uric acid increased 176.30 145.64 65 4429 15482 42601359
Hyperphosphataemia 168.48 145.64 60 4434 12944 42603897
Ventricular fibrillation 159.56 145.64 73 4421 30050 42586791

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 286.85 140.10 75 4672 14180 110570372
Blood phosphorus increased 248.82 140.10 69 4678 16271 110568281
Myasthenia gravis 247.50 140.10 73 4674 21438 110563114
Appendicitis 239.73 140.10 76 4671 28388 110556164
Blood uric acid increased 217.10 140.10 66 4681 21463 110563089
Hyperphosphataemia 212.34 140.10 61 4686 16320 110568232
Ventricular fibrillation 204.44 140.10 74 4673 41239 110543313
Cardiogenic shock 170.66 140.10 71 4676 57267 110527285
Incorrect route of product administration 169.64 140.10 73 4674 63988 110520564
Hypophosphataemia 166.23 140.10 60 4687 33122 110551430
Analgesic therapy 154.54 140.10 40 4707 7244 110577308
Neuralgia 154.33 140.10 63 4684 48415 110536137
Ascites 152.62 140.10 76 4671 92732 110491820
Somnolence 151.65 140.10 115 4632 297334 110287218
Drug therapy 149.66 140.10 39 4708 7252 110577300
Sleep disorder therapy 143.92 140.10 38 4709 7433 110577119
Bacterial infection 143.71 140.10 59 4688 45977 110538575

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D02BA01 DERMATOLOGICALS
EMOLLIENTS AND PROTECTIVES
PROTECTIVES AGAINST UV-RADIATION
Protectives against UV-radiation for topical use
ATC D11AX23 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Other dermatologicals
FDA CS M0022792 Vitamin B Complex
FDA EPC N0000175714 Vitamin B Complex Member
CHEBI has role CHEBI:75772 <em>Saccharomyces cerevisiae </em> metabolite
CHEBI has role CHEBI:76924 plant metabolite
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:50904 allergen

Related Drugs by ATC class:

D02BA Protectives against UV-radiation for topical use 1 drug
octinoxate
D11AX Other dermatologicals 20 drugs
brimonidinecaffeinecalcium gluconatedeoxycholic aciddiclofenaceflornithinefinasteridegamolenic acidhydrogen peroxidehydroquinoneivermectinlithium succinate show all 20 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Induratio penis plastica indication 1335005 DOID:8616
Pemphigus indication 65172003 DOID:9182
Systemic sclerosis indication 89155008 DOID:418
Morphea indication 201049004
Dermatomyositis indication 396230008 DOID:10223
Anorexia nervosa contraindication 56882008 DOID:8689
Kidney disease contraindication 90708001 DOID:557




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.65 acidic
pKa2 2.29 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Carbonic anhydrase 2 Enzyme Ki 5.09 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 5.08 CHEMBL
Acetylcholinesterase Enzyme IC50 7.45 CHEMBL
Polyphenol oxidase 2 Enzyme IC50 5.42 CHEMBL
Dihydropteroate synthase Enzyme Kd 5.25 CHEMBL

External reference:

IDSource
4019089 VUID
N0000147349 NUI
D02456 KEGG_DRUG
138-84-1 SECONDARY_CAS_RN
4018418 VANDF
4019089 VANDF
C0000473 UMLSCUI
CHEBI:22495 CHEBI
PAB PDB_CHEM_ID
CHEMBL542 ChEMBL_ID
CHEMBL1564391 ChEMBL_ID
DB02362 DRUGBANK_ID
TL2TJE8QTX UNII
978 PUBCHEM_CID
142141 RXNORM
41627 MMSL
5231 MMSL
5335 MMSL
5490 MMSL
NOCODE MMSL
d00331 MMSL
d04184 MMSL
001006 NDDF
001007 NDDF
001966 NDDF
002325 NDDF
002326 NDDF
002338 NDDF
329290002 SNOMEDCT_US
373489001 SNOMEDCT_US
395838004 SNOMEDCT_US
39707000 SNOMEDCT_US
D010129 MESH_DESCRIPTOR_UI
TL2TJE8QTX INXIGHT DRUGS

Pharmaceutical products:

None